Showing 2621-2630 of 8642 results for "".
Top 2023 Psoriasis Treatment Announcements
https://practicaldermatology.com/topics/psoriasis/top-2023-psoriasis-treatment-announcements/20232/Daniel Schlessinger, MD, Mohs Micrographic Surgery and Cosmetic Dermatology Fellow at Northwestern University, reviews for Practical Dermatology® some of the important psoriasis drug approval news of 2023.Dermatology Innovations
https://practicaldermatology.com/topics/psoriasis/dermatology-innovations/20044/From topical therapies to JAK inhibitors, there are many new drugs available to treat a wide variety of dermatologic conditions. Neal Bhatia, MD reviews what's new for atopic dermatitis, alopecia areata, scabies, lice, onychomycosis, and more. Plus, he discusses the importance of new delivery systemAtopic Dermatitis in the Spotlight: Uncovering the Burden Beneath the Skin?
https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-in-the-spotlight-uncovering-the-burden-beneath-the-skin/20030/Highlighting the common symptoms experienced by patients and their perceived burden (including itch, lesions, pain and sleep disturbance), the impact of symptoms and particularly sleep disturbance on quality of life, activity, and mental health and the different atopic dermatitis phenotypes and relaDermWireTV: NPF on Boosters; Galderma Raises Awareness, World Eczema Day, and more
https://practicaldermatology.com/topics/psoriasis/dermwiretv-npf-on-boosters-galderma-raises-awareness-world-eczema-day-and-more/20002/Launched on World Eczema Day, the Global Patient Initiative to Improve Eczema Care represents 11 patient organizations from eight countries. The initiative is supported with funding from LEO Pharma. GlobalSkin marked World Eczema Day by calling on health care professionals, health policy decision maDermWireTV: 2020 in Review
https://practicaldermatology.com/topics/psoriasis/dermwiretv-2020-in-review/19882/Crisaborole ointment became the first and only steroid-free, topical prescription medication for mild to moderate AD in patients as young as three months of age. Ustekinumab is approved for pediatric patients with moderate to severe plaque psoriasis. FDA approved ixekizumab injection, 80mg/mL for tActinic Keratosis: Therapy Overview
https://practicaldermatology.com/topics/skin-cancer-photoprotection/actinic-keratosis-therapy-overview/19732/Joel Cohen, MD interviews George Martin, MD about the latest developments in actinic keratosis. Dr. Martin said he is eagerly awaiting regulatory review of tirbanibulin, which showed promising results in clinical trials. The two also discuss practical tips and nuances of using 5FU in practice. *Be sModifying Masseters and More
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/modifying-masseters-and-more/19698/Artful use of neurotoxin in the masseters and parotid glands can help thin the appearance of the face. Chytra Anand, MD discusses her approach and talks about treatments used in her home country of India.New Toxin Textbook Hits Shelves
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-toxin-textbook-hits-shelves/18321/Available at Wiley-Blackwell and on Amazon.com, “Botulinum Toxins: Cosmetic and Clinical Applications” offers up-to-date info on neuromodulators in the US and abroad, along with tips on how to use them on the face and body. Joel Cohen, MD shares details about his new textbook.Therapeutic Advancements in Dermatology
https://practicaldermatology.com/topics/psoriasis/therapeutic-advancements-in-dermatology/18347/What therapeutic innovations define the specialty of dermatology? From significant strides in managing STDs and battling skin cancer to the harnessing of retinoids and the integration of biologics, dermatology has remained at the leading edge of medicine. Take a look at the specialty's top advancemeIs Your Financial Advisor Working for You
https://practicaldermatology.com/topics/practice-management/is-your-financial-advisor-working-for-you/18367/OJM Group Wealth Advisor, Andrew Taylor, CFP discusses the importance of working with an advisor with a "fiduciary" vs. "suitability" standard, and outlines other questions to ask when determining if your advisor is working in your best interest. Click here to request or download a free copy of Weal